Categories: HealthcareNews

Simulab Corporation Names Stephen Hertz as Chief Commercial Officer

SEATTLE, WA / ACCESSWIRE / December 2, 2024 / Simulab Corporation has appointed Stephen Hertz as its Chief Commercial Officer (CCO), effective immediately. Hertz will lead all sales and marketing functions and advance the company’s mission to improve medical simulation training worldwide.

“We are very happy with Stephen’s growth and contributions at Simulab over the past 11 years,” states Christopher Toly, Founder and Chief Executive Officer of Simulab. “The team could not be more proud to have him leading the company’s efforts in growth and care for our partners worldwide.”

Stephen previously served as Vice President of Sales at Simulab, where he worked closely with the healthcare simulation community to ensure the company’s solutions address the evolving needs of educators, practitioners, and institutions. His leadership has driven innovation, strengthened customer relationships, and reinforced Simulab’s position as a trusted partner in advancing healthcare education through simulation.

“Stephen’s appointment marks an exciting new chapter for Simulab,” said Doug Beighle, FSSH, President of Simulab Corporation. “His expertise will help us better serve our customers by delivering innovative solutions and fostering stronger partnerships in healthcare and medical training.”

As CCO, Stephen will continue leading Simulab’s team while enhancing customer engagement, driving innovation in simulation, and building partnerships that support impactful healthcare education and training.

Founded in 1994 and headquartered in Seattle, WA, Simulab Corporation is a leader in soft-tissue healthcare simulation training. Its innovative, realistic procedural trainers help healthcare professionals master essential skills, advancing patient safety and care quality.

Contact Information

Christie Angino
Director of Marketing
cangino@simulab.com
425-606-7646

Source: Simulab Corporation

Staff

Recent Posts

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

9 minutes ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

14 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

17 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

17 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

17 hours ago